GCLC and breast cancer: Thus, NQO1 and GCLC may be i) new prognostic biomarkers, ii) novel therapeutic targets and iii) companion diagnostics, for predicting and overcoming tamoxifen-resistance in different subsets of ER(+) breast cancer patients [14, 15].